Redx Pharma Plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Redx Pharma Plc
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
Ex-suitor Yesod seemed keen again but it looks as though Redx Pharma is about to be acquired by Redmile after the US healthcare investor upped its stake in the oncology and fibrotic diseases specialist.
Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.
Redx's takeover talks with a consortium led by controversial biotech veteran Sam Waksal, who was jailed for five years over his role in the ImClone stock scandal in 2003, have been terminated but the UK biotech has received a financial lifeline from Redmile and Sofinnova.
- Other Names / Subsidiaries
- Redx Anti-Infectives Ltd.